Lv41
474 积分 2026-03-02 加入
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
2小时前
求助中
Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies
12小时前
已完结
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential
9天前
已完结
SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
9天前
已完结
HER3 in breast cancer: molecular insights, clinical implications, and therapeutic horizons
17天前
已完结
皖公网安备34019202002308
